Brokers Set Expectations for Amphastar Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) - Research analysts at Capital One Financial raised their FY2024 EPS estimates for shares of Amphastar Pharmaceuticals in a note issued to investors on Wednesday, April 17th. Capital One Financial analyst T. Chiang now anticipates that the company will post earnings per share of $3.48 for the year, up from their prior forecast of $3.43. The consensus estimate for Amphastar Pharmaceuticals' current full-year earnings is $3.42 per share.

Several other equities research analysts have also issued reports on AMPH. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. JPMorgan Chase & Co. initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They issued an "overweight" rating and a $60.00 price objective for the company. Finally, StockNews.com lowered shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, February 29th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, Amphastar Pharmaceuticals has an average rating of "Hold" and a consensus target price of $66.00.

Amphastar Pharmaceuticals Stock Up 3.5 %

Shares of AMPH stock traded up $1.36 on Friday, hitting $40.01. The company's stock had a trading volume of 410,091 shares, compared to its average volume of 463,758. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.17 and a quick ratio of 1.70. Amphastar Pharmaceuticals has a fifty-two week low of $35.62 and a fifty-two week high of $67.66. The firm's fifty day moving average price is $46.27 and its 200-day moving average price is $51.14. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of 15.51, a P/E/G ratio of 0.96 and a beta of 0.84.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The business had revenue of $178.11 million during the quarter, compared to analyst estimates of $174.90 million.

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 500 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $53.10, for a total transaction of $26,550.00. Following the completion of the transaction, the director now owns 80,333 shares of the company's stock, valued at approximately $4,265,682.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Floyd F. Petersen sold 500 shares of the business's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $53.10, for a total transaction of $26,550.00. Following the transaction, the director now owns 80,333 shares in the company, valued at approximately $4,265,682.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Michael A. Zasloff sold 12,500 shares of the business's stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total transaction of $589,750.00. Following the transaction, the director now owns 21,326 shares in the company, valued at approximately $1,006,160.68. The disclosure for this sale can be found here. Insiders sold a total of 14,000 shares of company stock valued at $660,860 in the last quarter. Insiders own 28.40% of the company's stock.

Institutional Trading of Amphastar Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMPH. TD Asset Management Inc increased its stake in Amphastar Pharmaceuticals by 449.0% in the fourth quarter. TD Asset Management Inc now owns 793,559 shares of the company's stock valued at $49,082,000 after acquiring an additional 649,001 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Amphastar Pharmaceuticals by 396.7% in the third quarter. Price T Rowe Associates Inc. MD now owns 808,731 shares of the company's stock valued at $22,727,000 after acquiring an additional 645,917 shares during the period. Epoch Investment Partners Inc. increased its stake in Amphastar Pharmaceuticals by 348.7% in the fourth quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company's stock valued at $36,648,000 after acquiring an additional 460,473 shares during the period. Boone Capital Management LLC bought a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at about $24,740,000. Finally, Bank of America Corp DE increased its stake in Amphastar Pharmaceuticals by 347.2% in the first quarter. Bank of America Corp DE now owns 290,737 shares of the company's stock valued at $10,903,000 after acquiring an additional 225,728 shares during the period. Institutional investors own 65.09% of the company's stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.